Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois. more
Time Frame | ASRT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.58% | -0.09% | 0.83% |
1-Month Return | -9.24% | 0.03% | 5.98% |
3-Month Return | -21.78% | -6.26% | 9.65% |
6-Month Return | 0.75% | 1.16% | 14.29% |
1-Year Return | -18.47% | 11.16% | 32.26% |
3-Year Return | -29.26% | 11.98% | 31.61% |
5-Year Return | -67.05% | 47.19% | 94.03% |
10-Year Return | -98.49% | 109.06% | 191.47% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 229.50M | 106.28M | 111.01M | 156.23M | 152.07M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":46.31,"profit":true},{"date":"2021-12-31","value":48.37,"profit":true},{"date":"2022-12-31","value":68.07,"profit":true},{"date":"2023-12-31","value":66.26,"profit":true}] |
Cost of Revenue | 9.51M | 19.87M | 15.83M | 18.75M | 27.02M | [{"date":"2019-12-31","value":35.18,"profit":true},{"date":"2020-12-31","value":73.55,"profit":true},{"date":"2021-12-31","value":58.59,"profit":true},{"date":"2022-12-31","value":69.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 220.00M | 86.40M | 95.18M | 137.49M | 125.05M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":39.27,"profit":true},{"date":"2021-12-31","value":43.26,"profit":true},{"date":"2022-12-31","value":62.49,"profit":true},{"date":"2023-12-31","value":56.84,"profit":true}] |
Gross Margin | 95.86% | 81.30% | 85.74% | 88.00% | 82.23% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":84.81,"profit":true},{"date":"2021-12-31","value":89.44,"profit":true},{"date":"2022-12-31","value":91.8,"profit":true},{"date":"2023-12-31","value":85.78,"profit":true}] |
Operating Expenses | 220.75M | 133.32M | 84.67M | 79.39M | 368.58M | [{"date":"2019-12-31","value":59.89,"profit":true},{"date":"2020-12-31","value":36.17,"profit":true},{"date":"2021-12-31","value":22.97,"profit":true},{"date":"2022-12-31","value":21.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 3.20M | (46.92M) | 9.42M | 57.81M | (243.54M) | [{"date":"2019-12-31","value":5.54,"profit":true},{"date":"2020-12-31","value":-81.15,"profit":false},{"date":"2021-12-31","value":16.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-421.24,"profit":false}] |
Total Non-Operating Income/Expense | (284.07M) | 20.72M | (20.20M) | (34.61M) | (23.82M) | [{"date":"2019-12-31","value":-1371.28,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-97.49,"profit":false},{"date":"2022-12-31","value":-167.06,"profit":false},{"date":"2023-12-31","value":-114.96,"profit":false}] |
Pre-Tax Income | (222.48M) | (45.51M) | (553.00K) | 31.17M | (254.05M) | [{"date":"2019-12-31","value":-713.87,"profit":false},{"date":"2020-12-31","value":-146.03,"profit":false},{"date":"2021-12-31","value":-1.77,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-815.16,"profit":false}] |
Income Taxes | (5.28M) | (17.37M) | 728.00K | (78.46M) | 77.89M | [{"date":"2019-12-31","value":-6.78,"profit":false},{"date":"2020-12-31","value":-22.3,"profit":false},{"date":"2021-12-31","value":0.93,"profit":true},{"date":"2022-12-31","value":-100.73,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (217.20M) | (28.14M) | (1.28M) | 109.63M | (331.94M) | [{"date":"2019-12-31","value":-198.13,"profit":false},{"date":"2020-12-31","value":-25.67,"profit":false},{"date":"2021-12-31","value":-1.17,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-302.8,"profit":false}] |
Income From Continuous Operations | (217.18M) | (28.14M) | (1.28M) | 109.63M | (331.94M) | [{"date":"2019-12-31","value":-198.12,"profit":false},{"date":"2020-12-31","value":-25.67,"profit":false},{"date":"2021-12-31","value":-1.17,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-302.8,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (217.20M) | (28.14M) | (1.28M) | 109.63M | (331.94M) | [{"date":"2019-12-31","value":-198.13,"profit":false},{"date":"2020-12-31","value":-25.67,"profit":false},{"date":"2021-12-31","value":-1.17,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-302.8,"profit":false}] |
EPS (Diluted) | 2.32 | 0.76 | 0.11 | 1.78 | (1.01) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":32.76,"profit":true},{"date":"2021-12-31","value":4.74,"profit":true},{"date":"2022-12-31","value":76.72,"profit":true},{"date":"2023-12-31","value":-43.53,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ASRT | |
---|---|
Cash Ratio | 0.98 |
Current Ratio | 2.01 |
Quick Ratio | 1.57 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ASRT | |
---|---|
ROA (LTM) | -1.44% |
ROE (LTM) | -42.36% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ASRT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.53 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.47 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ASRT | |
---|---|
Trailing PE | NM |
Forward PE | 12.48 |
P/S (TTM) | 0.73 |
P/B | 0.73 |
Price/FCF | NM |
EV/R | 0.37 |
EV/Ebitda | 4.03 |
PEG | 1.25 |
Assertio Therapeutics Inc (ASRT) share price today is $0.9621
Yes, Indians can buy shares of Assertio Therapeutics Inc (ASRT) on Vested. To buy Assertio Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ASRT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Assertio Therapeutics Inc (ASRT) via the Vested app. You can start investing in Assertio Therapeutics Inc (ASRT) with a minimum investment of $1.
You can invest in shares of Assertio Therapeutics Inc (ASRT) via Vested in three simple steps:
The 52-week high price of Assertio Therapeutics Inc (ASRT) is $1.8. The 52-week low price of Assertio Therapeutics Inc (ASRT) is $0.73.
The price-to-earnings (P/E) ratio of Assertio Therapeutics Inc (ASRT) is
The price-to-book (P/B) ratio of Assertio Therapeutics Inc (ASRT) is 0.73
The dividend yield of Assertio Therapeutics Inc (ASRT) is 0.00%
The market capitalization of Assertio Therapeutics Inc (ASRT) is $81.80M
The stock symbol (or ticker) of Assertio Therapeutics Inc is ASRT